

Hepatobiliary and Pancreas Disease-Oriented Team

Clinical Research Treatment Trial Flowchart



LOCOREGIONAL	FIRST LINE	SECOND LINE	THIRD LINE
<u>UCI 19-49</u> Cabo + Ipi/Nivo + TACE Coord: B. Nguyen Accrual: 24/35	<u>UCI 22-106</u> STAT3 ± Pembrolizumab or ± Atezolizumab and Bevacizumab (Slot request required) Coord: H. Nguyen Accrual: 10/15	<u>UCI 16-94</u> TATE + Nivolumab (includes gastric/GEJ) Coord: S. Duong Accrual: 34/48	
<u>UCI 23-75/ROUTE 90</u> Eye90 microspheres Coord: B. Nguyen Accrual: 3/15	<u>UCI 22-211</u> MED1572 (IgG1 mAb) ± Bev Suspended for additional cohort Coord: B. Nguyen Accrual: 3/8	<u>UCI 23-215</u> AZD5851 (GPC3 Autologous CAR-T) Central testing for GPC3 and no previous GPC3 treatment Suspended until Q1 2026	
ADJUVANT <u>UCI 25-136</u> Personalized Neoantigen DNA Vaccine (GNOS-PV02) vs. Surveillance High-Risk HCC DOT approved	<u>UCI 23-104</u> Livmoniplimab + Budigalimab Atezolizumab + Bevacizumab Tremelimumab + Durvalumab Suspended until Q1 2026 Coord: S. Duong Accrual: 3/7	<u>UCI 25-06</u> ABBV-324 (GPC3 ADC) vs. Lenvatinib Coord: M. Duron Accrual: 1/3	
		<u>UCI 24-09</u> RYZ801 (GPC3 radiotherapeutic) Pending imaging qualification Coord: V. Luong	
		<u>ETCTN 10703</u> Sapanisertib (mTOR kinase inhibitor) + Cabozantinib B-catenin positivity during Phase 2 only Coord: V. Luong	



SYSTEMIC + OPERATIVE

ETCTN 10608
Gemcitabine + Cisplatin +
Durva Neo/Adjuvant for **high-risk resectable ICC**

Reopen September 2025
Coord: H. Nguyen
Accrual: 2/3

UCI 23-99
Randomize, adjuvant
Rilvegostomig/placebo +
capecitabine or gem/cisplatin
after BTC resection

Coord: B. Nguyen
Accrual: 1/8

FIRST LINE

UCI 22-211
MED1572 (IgG1 mAb) or
AZD2936 (TIGIT) ±
gemcitabine and cisplatin

Coord: C. Kang
Accrual: 3/8

SECOND LINE+

ETCTN-10276
M3814 ± Avelumab +
Hypofraction Radiation

Coord: C. Kang
Accrual: 3/5

UCI 23-200
AZD0901 (CLND18 ADC)
Central prescreening

Suspended until Q1 2026
Coord: M. Duron
Accrual: 5/10

UCI 25-137
Nanvuranlat (LAT1 inhibitor)
vs. Physician choice
chemotherapy

Pending budget/CTA/IRB

BRAIN METASTASES

NRG BN013
SRS vs. FSRS RT

Brain RT naïve

Coord: M. Duron
Accrual: 1/5



BORDERLINE/ LOCALLY ADVANCED

ETCTN-10366

M3814 (Peposertib) + radiation
Coord: S. Duong
Accrual: 10/13

ETCTN-10464

Olaparib + Durvalumab + radiation

Coord: S. Duong
Accrual: 1/5

UCI 23-134

Padeliporfin Vascular targeted
photodynamic therapy

Pancreatic head/uncinate w/SMA

Coord: C. Kang
Accrual: 3/8

NRG-GI011

Dose escalated radiation

Coord: V. Luong
Accrual: 0/10

FIRST LINE LA/METASTATIC

UCI 23-200

AZD0901 (CLND18 ADC) with
NAL-IRI or Gemcitabine

Coord: S. Duong
Accrual: 5/10

ETCTN 10522

CA4948 + gemcitabine + nab-
paclitaxel

Coord: B. Nguyen
Accrual: 4/6

UCI 25-140

Narmafotinib w/mFOLFIRINOX
mPDAC diagnosed w/in 6 weeks of
treatment

Pending budget/CTA/IRB

UCI 22-51

ASP2138 (CLDN18.2 BiTe) with
FOLFIRINOX

Coord: P. Yang
Accrual: 31/35

UCI 25-120

Ponsegromab (GD15 blocker)
vs. placebo for cachexia

Pending Budget/CTA/IRB

FIRST AND SECOND LINE

UCI 24-105

Pitavastatin + Gemcitabine/Nab-paclitaxel
SD after 3 months of treatment w/gem/nab-paclitaxel

Pending budget

RECURRENT

Review Biomarker Based Solid Tumors Pages 6 and 7

UCI 24-08

SPEDOX -6 (Protein
encapsulated doxorubicin)
KRAS Mutation

Coord: B. Nguyen
Accrual: 4/67

UCI 24-113

BMS-986482 (Treg inducer)

Coord: S. Duong
Accrual: 2/5

BRAIN METASTASES

NRG BN013

SRS vs. FSRS RT

Brain RT naïve

Coord: M. Duron
Accrual: 1/5



ADJUVANT

S2104

Capecitabine + Temozolomide vs observation

Pancreatic NET Ki67 > 3%

Coord: J. Balague
Accrual: 0/2

SECOND LINE

ETCTN 10479

Lu-177 + Sunitinib

Well or moderately differentiated PNET
Up to one line of systemic therapy not including somatostatin

Coord: H. Nguyen
Accrual: 0/3

SECOND LINE+

ETCTN 10558

Lu-177 ± Triapine

NET w/positive 68 or 64 DOTATATE on scans

Coord: H. Nguyen
Accrual: 3/3

METASTATIC

UCI 24-138

Various Neuroendocrine including Gastroenteropancreatic NEN with DLL3 expression on IHC

PI: Dr. Park
Coord: V. Luong
Accrual: 0/5

UCI 25-75

NET/NEC solid tumors with SST2 expression

Pending IRB/Budget/CTA

Mutation based studies allowing Pancreatic, HCC, and Biliary cancers + other solid tumors

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

CLAUDIN 18.2

UCI 22-51

ASP2138 (CLDN18.2 BiTe)

Pancreatic and Gastric/GEJ

Coord: P. Yang
Accrual: 31/35

AKT1 E17K

UCI 25-28

ATV-1601 (ATK Inhibitor)

ATK1 E17K **local** testing

PI: Dr. Lavasani
PRMC approved

KRAS/NRAS

UCI 21-53

LY3537982 (KRAS G12C Inhibitor)

Coord: J. Choe
Accrual: 9/12

GERMLINE MUTATIONS

ETCTN-10528

Novobiocin (POLθ)
Germline mutations

Coord: H. Nguyen
Accrual: 0/5

MTAP

UCI 24-197

TNG456 (PRMT5 inhibitor)

MTAP NGS/IHC **local** testing

PI: Dr. Park
PRMC approved

TP53-Y220C

UCI 25-52

Rezatapopt (p53 reactivator)

TP53 Y220C **local** testing

PI: Dr. Arter
Coord: J. Balague
Accrual: 0/15

UCI 22-87
RMC-6236 (KRAS Inhibitor)

Pancreatic KRAS WT 2L

Coord: C. Kang
Accrual: 21/25

HER2

ETCTN-10495

(DS8201a + Neratinib)

Coord: M. Nguyen
Accrual: 2/7

ALK

UCI 21-241

NVL- 655 (ALK inhibitor)

PI: Dr. Nagasaka
Coord: M. Duron
Accrual: 20/25



Various solid tumors included, or have progressed on, exhausted all therapies, or not amenable to further treatment

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

UCI 22-26

CB-03-10 (Androgen and glucocorticoid antagonist)

All solid tumors

Coord: B. Nguyen
Accrual: 11/12

UCI 24-142

VET3-TGI (IL-12 and TGF- β inhibiting vaccine) $\pm$ Pembrolizumab
Intra-tumoral or IV

PI: Dr. Uchio
Coord: M. Duron
Accrual: 0/4

UCI 25-16

ODM-212 (Hippo pathway)

Reach out to coordinator for selected tumor types
(9/10/25 accepting PDAC)

Coord: P. Yang

BLOOD COLLECTION

UCI 21-124

ctDNA collection during HBP
workup

Coord: J. Balangué

Accrual: 16/17

UCI 23-10/PRECEDE

(Blood collection for early
detection of pancreatic
cancer)

Pending budget/contract

UCI 22-55

Blood and biomarker
collection for early detection
and diagnosis of DNA
Deficient Hereditary Cancers

Investigators: Dr. Jennifer
Valerin and Dr. Nicholas
Pannunzio